In a comparative study (in 2007), various detection kits had a
sensitivity between 69.6% and 77.5% and a
specificity between 87.8% and 96.4%. Despite the excellent performance of these
immunoassays, for example CCP-assays, they only provide a sensitivity comparable with that of
rheumatoid factor (RF). Moreover, analysis of the correlation of anti-CCP antibody titre with RA disease activity yielded conflicting results. However, novel test systems utilizing ACPA have been developed. Citrullinated vimentin is a very promising autoantigen in RA, and a suitable tool for studying this systemic
autoimmune disease. Vimentin is secreted and citrullinated by macrophages in response to apoptosis, or by pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha). A newly developed
ELISA system utilises genetically modified citrullinated vimentin (
MCV), a naturally occurring isoform of vimentin to optimize the performance of the test. Noteworthy are the findings of a recently published study that highly valuates anti-MCV test systems for diagnosing rheumatoid arthritis in anti-CCP-negative patients. However, data from all around the world vary substantially. Anti-CCP is also very useful in the early diagnosis of rheumatoid arthritis in high-risk groups, such as relatives of RA patients, although Silman and co-workers found that the concordance rate of developing RA was 15.4% among identical (monozygotic) twins and was 3.6% among fraternal (dizygotic) twins. Given that ACPA are more specific than rheumatoid factor, they are used to distinguish various causes of arthritis. Novel assays may be useful for monitoring disease activity and effects of RA therapy. The
reference ranges for blood tests of anti–citrullinated protein antibodies are: Anti-CCP is part of the 2010 ACR/EULAR classification criteria for
Rheumatoid Arthritis. Anti-CCP positivity is also a good prognostic marker for future radiographic damage, and possibly a marker to B-cell therapy responses including
rituximab. Combination of anti-CCP with other serological markers like
rheumatoid factor, 14-3-3η (
YWHAH) not only enhances the diagnostic capture rate but together with acute phase reactants either in early disease or at the time of diagnosis may be useful in predicting future outcomes. ==Other ACPAs and citrullinated targets in RA ==